Etanercept Market - Forecast(2021 - 2026)

Report Code: HCR 27386 Report Format: PDF + Excel (Delivery in 48 Hrs)
Etanercept Market Overview
Etanercept Market size is forecast to reach $19.8 billion by 2025, growing at a CAGR of 3.8% during the forecast period 2020-2025. Etanercept is a fully human recombinant molecule consisting of two soluble TNF receptor (p75) subunits fused to the Fc portion of human IgG1. It is sold under the brand name Enbrel among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. Growing prevalence of arthritis among the old age population, increasing frequencies of accidents and increasing investments of constant development of Etanercept Market products has resulted in a rise in demand of Etanercept across the globe. Etanercept Market Analysis is based on product type, application and geography.

Report Coverage
The report: “Etanercept Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Etanercept Market. 

By Product Type: Benepali, Enbrel, Others 
By Application: Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis (JIA), Others 
By Geography: North America, Europe, Asia-Pacific, Rest of the World
Key Takeaways
  • North America dominated the Etanercept Market in the year 2019 owing to favorable reimbursement scenario, acceptance of advanced techniques, and technologically advanced health care system. The Etanercept Market scope for different regions will be provided in the final report.
  • Growing incidences of lifestyle diseases among the masses, big investments by countries for better healthcare and major launches of products of Etanercept have helped in significant growth of Etanercept Market.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Etanercept Market Research report.
  • Lack of reimbursement policies in major market regions is anticipated to hamper the market growth of the Etanercept Industry.

Product Type - Segment Analysis
Benepali held the largest share in the product type segment of Etanercept Market in 2019 and is estimated to grow at a CAGR of 2.91% during the forecast period 2020-2025. Benepali, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Benepali is found to have better efficiencies and quicker actions. Benepali in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate, and is also given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Enbrel is set to be the fastest growing segment and will register the highest CAGR during the forecast period 2020-2025, owing to its favorable demand from customers and widening gap of its sale with other biosimilars in recent months.

Application - Segment Analysis
Rheumatoid Arthritis holds the major share in the application segment of Etanercept Market in 2019. Increasing prevalence of the arthritis and related diseases among the geriatric population, occurrence of biosimilars & biologics, and well developed and maintained authoritarian guidelines by governments have driven the growth of this segment in Etanercept Market.  Psoriatic Arthritis segment is poised to dominate the market with the highest CAGR during the forecast period 2020-2025, owing to targeted action of increasing consumer demand for cost-effective medicines with improved safety and efficacy profiles.

Geography - Segment Analysis
North America dominates the geography segment of Etanercept Market with a share of more than 36.71% in 2019, followed by Europe. Presence of key market players in this region and accessibility of modern treatment options have helped in the significant market growth in this region. Ageing population and the growing healthcare investments by government have also led to growing opportunities for this market. These factors have driven the market growth in this region. 
Asia-Pacific is estimated to grow at the fastest rate at a higher CAGR during the forecast period 2020-2025. Gradual rise in skilled physicians and high healthcare expenditure are factors that are anticipated to help in significant market growth.

Drivers – Etanercept Market

  • Growing incidences of lifestyle diseases among the masses
Lifestyle diseases like hypertension, diabetes mellitus, dyslipidemia and obesity are the major risk factors for the development of cardiovascular diseases. With rapid economic development and increasing investments in healthcare in recent years, Etanercept Market is poised to see significant market growth during the forecast period 2020-2025.

  • Big investments by companies for better healthcare
Cipla entered into a partnership in 2019 for the commercialization of key biosimilar in select emerging markets. This commercialization includes trastuzumab, bevacizumab, etanercept and pegfilgrastim. In November 2019, Samsung Biogen  entered an agreement with Biogen which provides an option to extend the commercialization term for Samsung Bioepis’ three anti-TNF biosimilars – BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) in Europe for additional five years. Regular market developments of these companies helps increase the growth of the market globally.

Challenges – Etanercept Market

  • Lack of reimbursement policies
High out-of-pocket payments (OOPs) for medicines, including co-payments, create a risk of lower treatment adherence and lower medicine consumption; this has a negative impact on health and investment sector. Lack of robust reimbursement systems and policies is set to put restraint on the market in upcoming years.

Etanercept Industry Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Etanercept Market. Etanercept Market revenue is primarily generated by manufacturing and distribution by the key market players. In 2019, Etanercept Market is consolidated by the top players present in the market. Etanercept Market top 10 companies are Pfizer, Takeda, Johnson & Johnson, GlaxoSmithKline, Samsung Bioepis, Roche, Cipla, Novartis, Celltrion and Clover Biopharmaceuticals among others.

Acquisitions/Product Launches
  • In July 2019, Cipla and Alvotech entered into a partnership for the commercialization of key biosimilar in select emerging markets. This commercialization includes trastuzumab, bevacizumab, etanercept and pegfilgrastim.
  • In November 2019, Samsung Biogen  entered an agreement with Biogen which provides an option to extend the commercialization term for Samsung Bioepis’ three anti-TNF biosimilars – BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) in Europe for additional five years.
  • In December 2019, Clover Biopharmaceuticals announced that the first patient was dosed in a Phase III trial of SCB-808, a proposed biosimilar to Enbrel (Etanercept) being developed in the prefilled syringe formulation for the treatment of rheumatic diseases, including ankylosing spondylitis and rheumatoid arthritis.

1. Etanercept Market Overview
    1.1 Definitions and Scope
2. Etanercept Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Product Type
    2.3 Key trends by Application
    2.4 Key trends by Geography
3. Etanercept Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Etanercept Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Etanercept Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Etanercept Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Etanercept Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Etanercept Market – By Product Type (Market Size –$Million/$Billion)
    8.1 Benepali
    8.2 Enbrel
    8.3 Others
9. Etanercept Market – By Application (Market Size –$Million/$Billion)
    9.1 Ankylosing Spondylitis
    9.2 Psoriatic Arthritis
    9.3 Rheumatoid Arthritis
    9.4 Juvenile Idiopathic Arthritis (JIA)
    9.5 Others
10. Etanercept Market - By Geography (Market Size –$Million/$Billion)
    10.1 North America
        10.1.1 U.S.
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 U.K.
        10.2.2 Germany
        10.2.3 France
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 India
        10.3.3 Japan
        10.3.4 South Korea
        10.3.5 Australia & New Zealand
        10.3.6 Rest of Asia-Pacific
    10.4 Rest of the World
        10.4.1 Middle-East 
        10.4.2 Africa
        10.4.3 South America
11. Etanercept Market - Entropy
12. Etanercept Market – Industry/Segment Competition Landscape  (Premium)
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key companies
        12.1.3 Market Share by Countries – Key Companies
        12.1.4 Best Practices for Companies
13. Etanercept Market – Key Company List by Country Premium (Premium)
14. Etanercept Market Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

LIST OF FIGURES

1.US Etanercept Market Revenue, 2019-2024 ($M)
2.Canada Etanercept Market Revenue, 2019-2024 ($M)
3.Mexico Etanercept Market Revenue, 2019-2024 ($M)
4.Brazil Etanercept Market Revenue, 2019-2024 ($M)
5.Argentina Etanercept Market Revenue, 2019-2024 ($M)
6.Peru Etanercept Market Revenue, 2019-2024 ($M)
7.Colombia Etanercept Market Revenue, 2019-2024 ($M)
8.Chile Etanercept Market Revenue, 2019-2024 ($M)
9.Rest of South America Etanercept Market Revenue, 2019-2024 ($M)
10.UK Etanercept Market Revenue, 2019-2024 ($M)
11.Germany Etanercept Market Revenue, 2019-2024 ($M)
12.France Etanercept Market Revenue, 2019-2024 ($M)
13.Italy Etanercept Market Revenue, 2019-2024 ($M)
14.Spain Etanercept Market Revenue, 2019-2024 ($M)
15.Rest of Europe Etanercept Market Revenue, 2019-2024 ($M)
16.China Etanercept Market Revenue, 2019-2024 ($M)
17.India Etanercept Market Revenue, 2019-2024 ($M)
18.Japan Etanercept Market Revenue, 2019-2024 ($M)
19.South Korea Etanercept Market Revenue, 2019-2024 ($M)
20.South Africa Etanercept Market Revenue, 2019-2024 ($M)
21.North America Etanercept By Application
22.South America Etanercept By Application
23.Europe Etanercept By Application
24.APAC Etanercept By Application
25.MENA Etanercept By Application
26.Pfizer Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Takeda Pharmaceutical Company Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Johnson Johnson, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Glaxosmithkline Pharmaceutical Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Samsung Bioepis Co , Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.F. Hoffmann-La Roche Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Cipla Limited, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Novartis International Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Celltrion Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Immunex Corporation, Sales /Revenue, 2015-2018 ($Mn/$Bn)